Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Keryx Biopharmaceuticals    KERX

KERYX BIOPHARMACEUTICALS (KERX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Keryx Biopharmaceuticals : Traders Favorite: Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/22/2013 | 08:05pm CEST

NEW YORK, April 22, 2013 -Bestdarnpennystocks.com, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Keryx Biopharmaceuticals, McDonald's Corporation, Merck & Co, Hertz Global Holdings.

Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 5.48% to $8.47. The company, on March 11, announced its results for the fourth quarter and year ended December 31, 2012. The net loss for the 4th quarter ended December 31, 2012 was $6.6 million, or $0.09 per share versus $8.4 million for quarter 2011, representing a decrease of $1.8 million and Net loss for the year ended December 31, 2012, was $22.7 million versus $28.1 million for the year ended December 31, 2011, representing a decrease in net loss of $5.4 million.

At December 31, 2012, the Company had cash, cash equivalents, interest receivable, and investment securities of $14.7 million, as compared to $39.5 million at December 31, 2011.

Has KERX Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=KERX (OR Just copy and paste the link)

McDonald's Corporation(NYSE:MCD) shares decreased 1.13% to $98.80. The company, on April 19, posted first-quarter profit that was little changed as same-store sales dropped in the U.S. for the first time since 2003 amid soft global demand. Net income was about $1.27 billion, or $1.26 share, compared with $1.27 billion, or $1.23, a year earlier. Analysts projected $1.26, the average of 29 estimates compiled by analyst.

Has MCD Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MCD (OR Just copy and paste the link)

Additionally, MCD?s stock had its ?buy? rating restated by analysts at Janney Montgomery Scott in a research report issued to clients and investors on April 16. They currently have a $115.00 price target on the stock.

Merck & Co., Inc.(NYSE:MRK) shares fell 0.38% to $47.31. The company, on April 1st reported that it will hold its first-quarter 2013 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Wednesday, May 1.

Has MRK Reached The Bottom and ready To Hit 52-week High? Find Out Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=MRK (OR Just copy and paste the link)

Additionally, the company, on April 10, announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration (FDA).

Hertz Global Holdings, Inc. (NYSE:HTZ) shares decreased 0.76% to $23.54. The company, on April 16, agreed to acquire a 20% stake in Beijing-based China Auto Rental Holdings Inc. to expand its presence in China's car-rental market. Financial terms weren't disclosed.

How Should Investors Trade HTZ Now? Get Free Trend Analysis Here http://bestdarnpennystocks.com/landing-new/home-aw2.php?code=HTZ (OR Just copy and paste the link)

Additionally, the company, on April 8, announced that its wholly-owned subsidiary, The Hertz Corporation ("Hertz"), has successfully completed a repricing of its currently outstanding $1,372 billion senior secured tranche B term loan facility. As part of the repricing, the tranche B term loans will be replaced by new tranche B-2 term loans.

About bestdarnpennystocks.com
bestdarnpennystocks.com?s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by bestdarnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. bestdarnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in bestdarnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.
Contacts:
bestdarnpennystocks.com
1419 Westwood Blvd Los Angeles, CA
90024-4911
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KERYX BIOPHARMACEUTICALS
04/20KERYX BIOPHARMACEUTICALS : Announces Late-breaking Ferric Citrate Abstract Accep..
AQ
04/19Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Acce..
GL
04/16KERYX BIOPHARMACEUTICALS : Receives 2018 Corporate Innovator Award from the Nati..
AQ
04/12KERYX BIOPHARMACEUTICALS : Today’s Research Reports on Stocks to Watch: Keryx Bi..
AC
04/11KERYX BIOPHARMACEUTICALS : Receives 2018 Corporate Innovator Award from the Nati..
AQ
04/11Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the Nat..
GL
04/06KERYX BIOPHARMACEUTICALS : Announces Publication of Data from the Phase 3 Trial ..
AQ
04/05KERYX BIOPHARMACEUTICALS : Announces Publication of Data from the Phase 3 Trial ..
AQ
04/04Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial..
GL
03/12KERYX BIOPHARMACEUTICALS : to Webcast its Presentation at the Cowen 38th Annual ..
AQ
More news
News from SeekingAlpha
02/15Tracking David Abrams' Abrams Capital Management Portfolio - Q4 2017 Update 
02/14Tracking Seth Klarman's Baupost Group Holdings - Q4 2017 Update 
02/08Keryx Biopharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides 
02/08YOUR DAILY PHARMA SCOOP : Abeona Surges, Gilead Results, Biogen Setback 
02/07Keryx Biopharmaceuticals' (KERX) CEO Gregory Madison on Q4 2017 Results - Ear.. 
Financials ($)
Sales 2018 107 M
EBIT 2018 -75,2 M
Net income 2018 -73,3 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 5,31x
Capi. / Sales 2019 3,31x
Capitalization 567 M
Chart KERYX BIOPHARMACEUTICALS
Duration : Period :
Keryx Biopharmaceuticals Technical Analysis Chart | KERX | US4925151015 | 4-Traders
Technical analysis trends KERYX BIOPHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 6,64 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Gregory P. Madison President, Chief Executive Officer & Director
Michael W. Rogers Chairman
Christine A. Carberry Chief Operating Officer & Senior Vice President
Scott A. Holmes Chief Financial Officer & Senior Vice President
John F. Neylan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
KERYX BIOPHARMACEUTICALS2.37%567
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 812
BEIGENE LTD (ADR)71.91%8 998